Close Menu

More articles about Cancer

The test is now the first FDA-cleared test for use with the SurePath collection medium and vial for processing cervical cancer screening samples.

Revisions to the reimbursement catalog went into effect July 1, but stakeholders are quarreling about a pre-authorization requirement in court.

According to Myriad, the NOVA study shows that myChoice HRD can double the number of ovarian cancer patients who will respond to niraparib compared to other tests.

However, the task force stopped short of recommending the use of Cologuard or other molecular assays over a variety of well-established non-molecular testing methods.

The technology is used in Qiagen's newly CE-marked test for cervical cancer and is complementary to human papillomavirus screening tests.

The company shared results supporting FoundationOne's ability to estimate genome-wide mutation burdens, as well as new data linking test results to patient outcomes.

The agency has approved the cobas EGFR Mutation Test v2 as a companion diagnostic for Genentech's non-small cell lung cancer drug Tarceva (erlotinib).

The colon cancer screening test is now covered in-network by the insurance company in Indiana, Ohio, Kentucky, Missouri, and Wisconsin.

The test uses the company's SIA platform, a protein biomarker technology that measures different protein isoform populations to assess patient disease states.

Noridian said it has identified new data that will "significantly impact" its proposed policy on biomarker tests for guiding adjuvant chemotherapy decisions.

The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies. 

Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining. 

The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.

The company is working on a number of new sales deals after its biggest distributor, Health Diagnostics Laboratory, filed for bankruptcy last year.

Under the agreement, members of the health plan will have covered access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

The study found that with use of the mass spec-based test, about a third of surgeries and total invasive procedures, including biopsies, could be avoided.

Under the agreements, members of Fortified Provider Network and Three Rivers Provider Network will now have access to Biocept's liquid biopsy tests.

Biocept's liquid biopsy diagnostic services are available to approximately 68 million people in MultiPlan's national PPO and complementary network.

The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform. 

The findings may help identify which patients would be the best candidates for radiation therapy immediately following surgical removal of the prostate.

Pages